Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Walker

Showing results (331-340 of 342) with videos related to

Pageof 35
Sort By:
Contemporary Clinical Trials|January 9, 2026
Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan AfricaDiana Anena, Elizabeth Chappell, Rashidah Nazzinda, et al.
Campbell Systematic Reviews|April 14, 2026
PROTOCOL: Effectiveness of Interventions for the Prevention and Treatment of Obesity in Children and Adolescents From Low- and Middle-Income Countries: A Systematic Review and Meta-AnalysisGerardo A Zavala, Muhammad Asim, Aliya Ayub, et al.
Science Advances|August 11, 2023
Emergent mechanical control of vascular morphogenesisJordan Whisler, Somayeh Shahreza, Karin Schlegelmilch, et al.
Contemporary Clinical Trials|April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 yearsAnna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV|April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialAdeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The New England Journal of Medicine|May 14, 2025
Second-Line Antiretroviral Therapy for Children Living with HIV in AfricaVictor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al.
Disease Models & Mechanisms|March 21, 2025
Microvascular aberrations found in human polycystic kidneys are an early feature in a Pkd1 mutant mouse modelDaniyal J Jafree, Charith Perera, Mary Ball, et al.
Lancet (London, England)|September 2, 2018
High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trialAnoop S V Shah, Atul Anand, Fiona E Strachan, et al.
The Journal of Clinical Investigation|July 15, 2025
Organ-specific features of human kidney lymphatics are disrupted in chronic transplant rejectionDaniyal J Jafree, Benjamin J Stewart, Karen L Price, et al.
Nature|December 4, 2015
Sustainable HIV treatment in Africa through viral-load-informed differentiated care, Andrew Phillips, Amir Shroufi, et al.
Pageof 35

Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
Contemporary Clinical Trials|January 9, 2026
Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan AfricaDiana Anena, Elizabeth Chappell, Rashidah Nazzinda, et al.
Campbell Systematic Reviews|April 14, 2026
PROTOCOL: Effectiveness of Interventions for the Prevention and Treatment of Obesity in Children and Adolescents From Low- and Middle-Income Countries: A Systematic Review and Meta-AnalysisGerardo A Zavala, Muhammad Asim, Aliya Ayub, et al.
Science Advances|August 11, 2023
Emergent mechanical control of vascular morphogenesisJordan Whisler, Somayeh Shahreza, Karin Schlegelmilch, et al.
Contemporary Clinical Trials|April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 yearsAnna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV|April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialAdeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The New England Journal of Medicine|May 14, 2025
Second-Line Antiretroviral Therapy for Children Living with HIV in AfricaVictor Musiime, Mutsa Bwakura-Dangarembizi, Alexander J Szubert, et al.
Disease Models & Mechanisms|March 21, 2025
Microvascular aberrations found in human polycystic kidneys are an early feature in a Pkd1 mutant mouse modelDaniyal J Jafree, Charith Perera, Mary Ball, et al.
Lancet (London, England)|September 2, 2018
High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trialAnoop S V Shah, Atul Anand, Fiona E Strachan, et al.
The Journal of Clinical Investigation|July 15, 2025
Organ-specific features of human kidney lymphatics are disrupted in chronic transplant rejectionDaniyal J Jafree, Benjamin J Stewart, Karen L Price, et al.
Nature|December 4, 2015
Sustainable HIV treatment in Africa through viral-load-informed differentiated care, Andrew Phillips, Amir Shroufi, et al.
Pageof 35